Migraines affect millions in the UK, yet are often misunderstood and underestimated. From throbbing pain and nausea to ...
Vanda Pharmaceuticals received FDA approval for Nereus for motion sickness, and its shares offer upside potential into 2026 ...
MedPage Today on MSN
FDA Greenlights First Motion Sickness Drug in More Than 40 Years
The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has ...
The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults ...
US FDA approves Vanda Pharma’s Nereus, an oral NK-1 receptor antagonist for prevention of vomiting induced by motion: Washington Friday, January 2, 2026, 15:00 Hrs [IST] Vanda P ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
That’s where Iacoe’s athletic background is an asset, Doyle added. Where Radiance has already built a solid foundation with ...
Process: Utilizes a “growth-at-a-reasonable price” (GARP) framework and identifies high-quality stocks by focusing on consistent growth of capital and lower volatility; the portfolio seeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback